Actively Recruiting
Cancer Vaccine Targeting Mutated GNAS Combined With PD-1 Inhibitor for Adults With Pseudomyxoma Peritonei
Led by Oslo University Hospital · Updated on 2026-01-14
10
Participants Needed
1
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Pseudomyxoma peritonei PMP is a rare, slow-growing abdominal cancer that often starts in ruptured appendiceal tumors and leads to tumor and mucin buildup in the abdomen. Standard treatment includes surgery and heated chemotherapy, which cures about half of the patients, but options are limited for those with unresectable or recurrent disease. Researchers found that PMP patients have a strong immune response to mutated GNAS but this response is insufficient due to immune checkpoint molecule activity, providing a reason to test a vaccine targeting mutated GNAS combined with an immune checkpoint inhibitor. Participants will receive the Pseudovax peptide vaccine with the adjuvant granulocyte-macrophage colony-stimulating factor GM-CSF. Starting from week 13, the PD-1 inhibitor tislelizumab will be added for up to 21 months, continuing until disease progression, unacceptable side effects, withdrawal, or investigator decision. This combination aims to stimulate immune response against tumor cells while restoring anticancer immunity. During the study, participants will be monitored for safety and immune response from start of treatment through six months after the last dose and for up to two years of treatment. Researchers will assess tumor progression and survival, perform biopsies, and conduct various laboratory tests to evaluate the effects of the vaccine and immune checkpoint inhibitor. The study involves regular visits and follow-ups to ensure participant safety and measure treatment impact.
CONDITIONS
Brief Title
Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei
Research Team
G
Geir Olav Hjortland, Medical Doctor - Oncologist
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here